Avoro Capital Advisors Reduces $11M in BioCryst Pharmaceuticals, Inc. ($BCRX)

Avoro Capital Advisors has completely exited its position in BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). The fund sold all 1.25 million shares it held, leaving no shares in the company as of the end of the fourth quarter 2025, according to its latest filing with the SEC.

What Changed in Avoro Capital Advisors' BioCryst Pharmaceuticals Position

Avoro Capital Advisors reduced its stake in BioCryst Pharmaceuticals by 1.25 million shares, eliminating its entire position. Prior to this move, the fund held 1.25 million shares. This complete sell-off represents a 100% reduction in their investment in the biotechnology company.

Other Institutional Activity in BioCryst Pharmaceuticals

Several other institutional investors adjusted their holdings in BioCryst Pharmaceuticals. BlackRock, Inc. increased its stake by 1,513,197 shares, ending with 22,650,988 shares valued at about $215.6 million. RA Capital Management, L.P. maintained its position with 15,827,186 shares worth approximately $150.7 million. Deerfield Management Company, L.P. added 697,000 shares, bringing its total to 15,038,000 shares, valued at $143.2 million. State Street Corp also increased its holdings by 1,135,149 shares, resulting in a total of 12,208,360 shares worth $116.2 million.

BioCryst Pharmaceuticals Stock Snapshot

Shares of BioCryst Pharmaceuticals (NasdaqGS: BCRX) are trading around $8.70. The company has a market capitalization of about $2.21 billion and a forward P/E ratio of 12.79. Its beta is 0.565, indicating lower volatility compared to the market. The stock's 52-week range is between $6.00 and $10.47, with a 50-day moving average of $8.95 and a 200-day moving average of $7.92. BioCryst has a current ratio of 1.91 and a quick ratio of 1.78.

Recent Earnings

In its most recent earnings report, BioCryst Pharmaceuticals posted revenue of approximately $885.7 million, reflecting a growth rate of 7.5%. The company reported a net margin of -51.7%. The next earnings date is scheduled for May 6, 2026.

Insider Buying and Selling at BioCryst Pharmaceuticals, Inc.

Insider activity at BioCryst Pharmaceuticals includes several purchases on May 29, 2026. Jill Milne and Steven Frank each acquired 1,262 shares at an average price of $8.91. Vincent Milano bought 1,122 shares, while Amy McKee and Jon Stonehouse each purchased 631 shares at the same price. On May 18, 2026, Amy McKee sold 11,180 shares at an average price of $8.97.

Analysts Set New Price Targets

Analysts have been active in assessing BioCryst Pharmaceuticals' prospects. On May 7, 2026, both Citizens and Wedbush maintained their 'buy' ratings with price targets of $28 and $21, respectively. Needham also reiterated a 'buy' rating with a $16 target on May 6, 2026. The consensus among analysts is a 'buy' with a mean target price of $21.30 based on 10 opinions.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a biotechnology company based in Durham, North Carolina. It focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets products like RAPIVAB for influenza and ORLADEYO for HAE. BioCryst is also advancing its pipeline with treatments for conditions such as netherton syndrome and diabetic macular edema. Led by CEO Mr. Charles K. Gayer, the company employs approximately 435 people.

Bottom Line

Avoro Capital Advisors' complete exit from BioCryst Pharmaceuticals is a notable move in the biotech sector, reflecting a shift in its investment strategy. Investors often watch such changes closely, although it's important to remember that 13F filings are backward-looking and may not represent current positions. BioCryst continues to develop its product pipeline while maintaining interest from other institutional investors and analysts.